AMD Shows Data Centers Now Carry The Company

Driven Brands Holdings said in an 8-K filed Nov. 3 that its Audit Committee concluded on Oct. 31 that financial statements for fiscal 2023, 2024 and 2025, plus 2026 quarterly reports, contain material errors and should not be relied upon. Fixed asset accounting is the main category. The auto services operator will miss the Nov. 5 deadline for its Form 10-Q covering the quarter ended Sept. 26 and intends to file a Form 12b-25 by Nov. 6. The company also revised its 2026 outlook alongside the restatement.

The business is a $1.9 billion market cap company with $1.9 billion in revenue and a stated net margin of 9.9%, but those margins come from statements the company now says are unreliable. An Altman Z score of 0.9 sits in the weak zone, and the Street's Buy rating predates the restatement. A shareholder-lawsuit notice dated Oct. 29 already circulated before the filing. Fixed asset errors usually change depreciation and therefore earnings, so every trailing multiple on the stock, including its 10.6 P/E, is provisional.

GoodRx told the SEC on Nov. 2 that its Audit and Risk Committee concluded on Oct. 27 that results for the quarters ended Mar. 31 and Jun. 30, 2026 should no longer be relied upon. Pharma Direct revenue was understated by $7.5 million in one period and $22.3 million in the other under ASC 606. The error runs in the favourable direction for the top line, but the company expects to report material weaknesses in internal control for each affected period, and the figures remain preliminary.

On a business with $797 million in annual revenue, roughly $30 million is not trivial, and it lands on a company with a 3.8% net margin and an Altman Z score of 0.3. The market cap is $1.2 billion and the stock sits near $3.49 with a Hold rating. A bullish Oct. 31 piece called this a painful transition that pays off, and the company launched an employer weight-loss offering on Oct. 29. Both narratives now rest on numbers still being rewritten.

Karyopharm Therapeutics and a subsidiary filed Chapter 11 petitions on Nov. 2 in the Southern District of Texas, Houston Division, according to an 8-K. A restructuring support agreement covers 100% of funded debt. Ayrmid Ltd. is the stalking horse bidder for a merger with the reorganised company. The detail for shareholders is blunt: existing common and preferred equity will be cancelled with no distribution, which means the stock's residual value in this process is nil on the terms filed.

A stalking horse bid sets a floor in a court-supervised sale, and other bidders can still top it, but an agreement covering all funded debt suggests lenders have already chosen their path. Debt holders effectively take control of the outcome, and the equity is the cost of that deal. Anyone holding the stock into the open is holding a security the company itself says will receive nothing. The sale process and court calendar will determine how soon the shares cease to trade.

Uber reports third-quarter earnings before the opening bell on Wednesday, Nov. 4. The company has a $136 billion market cap, $52 billion in revenue, a 19.3% net margin and a P/E near 14, and the stock trades around $66.60 with a Buy rating. Benzinga's preview points to recent forecast changes from the analysts with the best track records, though the dossier does not give the new estimates. Pershing Square's third-quarter portfolio letter, also dated Nov. 4, cites higher margins and returns on capital.

The question hanging over the print is autonomy. A Nov. 3 earnings preview framed Uber, Lyft and DoorDash as facing an autonomous question as Tesla and Alphabet push robotaxi efforts. Tesla was itself down about 4% premarket on Nov. 4, and its stock carries a 402 P/E that prices in a lot of that threat. Management commentary on partnerships with autonomous operators will matter more than the quarter's gross bookings, and OpenAI hiring an Uber communications executive on Nov. 3 adds a footnote.